Matches in Wikidata for { <http://www.wikidata.org/entity/Q53083735> ?p ?o ?g. }
- Q53083735 description "2011 nî lūn-bûn" @default.
- Q53083735 description "2011年の論文" @default.
- Q53083735 description "2011年学术文章" @default.
- Q53083735 description "2011年学术文章" @default.
- Q53083735 description "2011年学术文章" @default.
- Q53083735 description "2011年学术文章" @default.
- Q53083735 description "2011年学术文章" @default.
- Q53083735 description "2011年学术文章" @default.
- Q53083735 description "2011年學術文章" @default.
- Q53083735 description "2011年學術文章" @default.
- Q53083735 description "2011年學術文章" @default.
- Q53083735 description "2011年學術文章" @default.
- Q53083735 description "2011年學術文章" @default.
- Q53083735 description "2011년 논문" @default.
- Q53083735 description "article científic" @default.
- Q53083735 description "article scientific" @default.
- Q53083735 description "article scientifique" @default.
- Q53083735 description "articol științific" @default.
- Q53083735 description "articolo scientifico" @default.
- Q53083735 description "artigo científico" @default.
- Q53083735 description "artigo científico" @default.
- Q53083735 description "artigo científico" @default.
- Q53083735 description "artikel ilmiah" @default.
- Q53083735 description "artikull shkencor" @default.
- Q53083735 description "artikulong pang-agham" @default.
- Q53083735 description "artykuł naukowy" @default.
- Q53083735 description "artículo científico publicado en 2011" @default.
- Q53083735 description "artículu científicu" @default.
- Q53083735 description "bilimsel makale" @default.
- Q53083735 description "bài báo khoa học" @default.
- Q53083735 description "naučni članak" @default.
- Q53083735 description "scienca artikolo" @default.
- Q53083735 description "scientific article published on 29 April 2011" @default.
- Q53083735 description "scientific article published on 29 April 2011" @default.
- Q53083735 description "scientific article published on 29 April 2011" @default.
- Q53083735 description "teaduslik artikkel" @default.
- Q53083735 description "tieteellinen artikkeli" @default.
- Q53083735 description "tudományos cikk" @default.
- Q53083735 description "vedecký článok" @default.
- Q53083735 description "vetenskaplig artikel" @default.
- Q53083735 description "videnskabelig artikel" @default.
- Q53083735 description "vitenskapelig artikkel" @default.
- Q53083735 description "vitskapeleg artikkel" @default.
- Q53083735 description "vědecký článek" @default.
- Q53083735 description "wetenschappelijk artikel" @default.
- Q53083735 description "wissenschaftlicher Artikel" @default.
- Q53083735 description "επιστημονικό άρθρο" @default.
- Q53083735 description "мақолаи илмӣ" @default.
- Q53083735 description "наукова стаття, опублікована у квітні 2011" @default.
- Q53083735 description "научна статия" @default.
- Q53083735 description "научная статья" @default.
- Q53083735 description "научни чланак" @default.
- Q53083735 description "научни чланак" @default.
- Q53083735 description "מאמר מדעי" @default.
- Q53083735 description "مقالة علمية نشرت في 29 أبريل 2011" @default.
- Q53083735 description "২৯ এপ্রিল ২০১১-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q53083735 description "บทความทางวิทยาศาสตร์" @default.
- Q53083735 description "სამეცნიერო სტატია" @default.
- Q53083735 name "[Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European medicines agency: a multicenter observational study]." @default.
- Q53083735 name "[Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European medicines agency: a multicenter observational study]." @default.
- Q53083735 type Item @default.
- Q53083735 label "[Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European medicines agency: a multicenter observational study]." @default.
- Q53083735 label "[Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European medicines agency: a multicenter observational study]." @default.
- Q53083735 prefLabel "[Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European medicines agency: a multicenter observational study]." @default.
- Q53083735 prefLabel "[Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European medicines agency: a multicenter observational study]." @default.
- Q53083735 P1433 Q53083735-E9740641-2E50-426B-BACD-8232EFE84737 @default.
- Q53083735 P1476 Q53083735-17E6E238-876E-43D2-B172-6B7B00DB61EF @default.
- Q53083735 P2093 Q53083735-03AC4C25-96C5-4DCE-A5EB-693955D5A69C @default.
- Q53083735 P2093 Q53083735-1CC63CDF-BB02-4061-957C-F4A9C0CCAE82 @default.
- Q53083735 P2093 Q53083735-3A9589A5-2280-4FB6-93C5-0CFD9378917C @default.
- Q53083735 P2093 Q53083735-4193F7D0-B65C-44FB-AB13-99DD04C689F3 @default.
- Q53083735 P2093 Q53083735-6E109E56-98B4-4F10-884A-D878ABD5904E @default.
- Q53083735 P2093 Q53083735-76D61237-1DB3-4318-9D0D-51064BD09773 @default.
- Q53083735 P2093 Q53083735-7B4A07A1-11A7-43D8-9F48-B89848E4B029 @default.
- Q53083735 P2093 Q53083735-87945A63-9B8E-4DB7-B395-2BE5D8F02465 @default.
- Q53083735 P2093 Q53083735-B2015E50-3240-4773-AB23-172EF7964683 @default.
- Q53083735 P2093 Q53083735-BC16FB27-A672-4375-8C48-EDA2482729EA @default.
- Q53083735 P2093 Q53083735-BC39BD1C-2026-4045-9B11-CF08613825EE @default.
- Q53083735 P2093 Q53083735-D5D0954D-FECD-4E41-B9D0-2BFC45246ACC @default.
- Q53083735 P2093 Q53083735-FF2D1D1D-94DD-4E9F-A49B-12F6693C8817 @default.
- Q53083735 P304 Q53083735-53B3AE22-E310-402D-968C-938E388C4A47 @default.
- Q53083735 P31 Q53083735-FF3536AD-27F2-4BCB-9E2F-C174157798A4 @default.
- Q53083735 P356 Q53083735-EED9B67F-A16B-4170-A75A-B8BE0F664BA6 @default.
- Q53083735 P407 Q53083735-9DECA7AC-7577-4B1F-9BD5-5F5AA2AC5E85 @default.
- Q53083735 P433 Q53083735-1E001CD1-371F-4EBB-8665-1ED7BB9FA94A @default.
- Q53083735 P478 Q53083735-D9C4B87A-E3E9-4177-8255-A3ACB6FBBA0F @default.
- Q53083735 P50 Q53083735-5201D90A-0261-4523-B075-3F0202597254 @default.
- Q53083735 P50 Q53083735-5A16A269-9472-439C-AC9E-58F8A17E5B6B @default.
- Q53083735 P50 Q53083735-7A4C169A-03E0-4BA9-A819-B62783A4E209 @default.
- Q53083735 P577 Q53083735-FA9A13A1-9DE3-49F0-BB3C-C39C00597B1C @default.
- Q53083735 P5875 Q53083735-FCAB6EDC-51F3-4E8D-B413-D82A38A22329 @default.
- Q53083735 P698 Q53083735-B79E8E75-8FC7-4078-AFA1-8336D03A4485 @default.
- Q53083735 P8608 Q53083735-D1D96572-C1AE-4FE1-A96F-E54EF490F3C4 @default.
- Q53083735 P356 J.AD.2010.12.013 @default.
- Q53083735 P698 21530928 @default.
- Q53083735 P1433 Q15746074 @default.
- Q53083735 P1476 "[Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European medicines agency: a multicenter observational study]." @default.
- Q53083735 P2093 "C Ferrándiz" @default.
- Q53083735 P2093 "C Muñoz-Santos" @default.
- Q53083735 P2093 "E Daudén" @default.